Last reviewed · How we verify
conbercept, Fixed
conbercept, Fixed is a VEGF decoy receptor Small molecule drug developed by Chengdu Kanghong Biotech Co., Ltd.. It is currently in Phase 3 development for Diabetic macular edema.
Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.
Conbercept is a protein-based inhibitor of vascular endothelial growth factor A, used to treat conditions such as choroidal neovascularization secondary to degenerative myopia and diabetic macular edema. It is administered via injection, with fixed and PRN (as needed) dosing regimens available.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | conbercept, Fixed |
|---|---|
| Sponsor | Chengdu Kanghong Biotech Co., Ltd. |
| Drug class | VEGF decoy receptor |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Conbercept works by binding to vascular endothelial growth factor (VEGF) and preventing it from interacting with its receptors on the surface of endothelial cells, thereby inhibiting angiogenesis. This mechanism of action is thought to be responsible for its anti-tumor and anti-angiogenic effects.
Approved indications
- Diabetic macular edema
Common side effects
- conjunctival hemorrhage
- eye pain
- conjunctival hyperemia
Key clinical trials
- Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema (NA)
- A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conbercept, Fixed CI brief — competitive landscape report
- conbercept, Fixed updates RSS · CI watch RSS
- Chengdu Kanghong Biotech Co., Ltd. portfolio CI
Frequently asked questions about conbercept, Fixed
What is conbercept, Fixed?
How does conbercept, Fixed work?
What is conbercept, Fixed used for?
Who makes conbercept, Fixed?
What drug class is conbercept, Fixed in?
What development phase is conbercept, Fixed in?
What are the side effects of conbercept, Fixed?
What does conbercept, Fixed target?
Related
- Drug class: All VEGF decoy receptor drugs
- Target: All drugs targeting VEGF
- Manufacturer: Chengdu Kanghong Biotech Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Diabetic macular edema
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing